AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions
Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, with the shares at 13,064p. The bank's analyst judged the company's investor event at the American Society of Clinical Oncology (ASCO) annual conference in Chicago as broadly incremental, acknowledging AZ's formidable oncology track record while pointing to unresolved questions that temper enthusiasm.
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical companies, with no major plenary presentations and little data capable of moving share prices materially. But beneath the quiet surface, both AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and Roche emerged with important questions to answer about the commercial futures of key pipeline assets.
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial
Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug Wainua, expected in the third quarter of 2026. Wainua is a TTR-silencer, a drug that suppresses production of a protein called transthyretin (TTR) which can misfold and accumulate in the heart and nerves, causing a progressive condition known as ATTR-cardiomyopathy (ATTR-CM).
CelLBxHealth signs master services agreement with AstraZeneca
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell (CTC) intelligence company, has signed a master services agreement with AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical group. The deal establishes CelLBxHealth as a qualified service provider to the Anglo-Swedish giant, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples using its Parsortix platform.
FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer
AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
How Big Pharma Is Turning Industrial Heat Into A Strategic Asset
Inside a pharmaceutical plant, heat is everywhere—and until recently, almost nobody was paying attention to it.
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.
AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer
AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.
AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins
I am initiating AstraZeneca at a "Strong Buy," driven by robust Q1 2026 revenue growth and portfolio momentum. The company's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively. Positive phase 3 data for IMFINZI in unresectable HCC and ULTOMIRIS in IgAN unlock significant expansion opportunities.
AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings
AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy
AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.
Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
